Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Bipolar disorder
Pharma
15 years later, Vanda secures another FDA nod for Fanapt
The FDA has signed off on Vanda Pharmaceuticals' Fanapt to treat adults with manic or mixed episodes associated with bipolar I disorder.
Kevin Dunleavy
Apr 3, 2024 11:04am
Alkermes reports strong trajectory for Lybalvi, shares up 10%
Feb 15, 2024 1:10pm
Intra-Cellular re-ups winning ad as bipolar drug builds momentum
Aug 8, 2023 12:51pm
New Alkermes ad wants Lybalvi to help patients 'push back'
Jun 7, 2023 9:20am
FDA signs off on Otsuka and Lundbeck's longer-acting Abilify
Apr 28, 2023 11:00am
Intra-Cellular's Caplyta posts sweeping win in depression trial
Mar 29, 2023 11:30am